Have you or your loved ones been diagnosed with malignant ovarian brenner tumor?
You may be eligible to participate in a malignant ovarian brenner tumor clinical trial.
Have you or your loved ones been diagnosed with malignant ovarian brenner tumor? You may be eligible to participate in a malignant ovarian brenner tumor clinical trial.
What is a clinical trial? Is participating in a clinical trial right for you? Learn more
Malignant Ovarian Brenner Tumor Clinical Trial in Rochester MN
Have you or your loved ones been diagnosed with malignant ovarian brenner tumor?
You may be eligible to participate in a malignant ovarian brenner tumor clinical trial.
Have you or your loved ones been diagnosed with malignant ovarian brenner tumor? You may be eligible to participate in a malignant ovarian brenner tumor clinical trial.
Recruiting
Male & Female
18 Years +
This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.
Details for the study
Brief Title
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Official Title
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
Brief Summary
This phase I/II trial studies the side effects and best dose of oncolytic measles virus <br /> encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to <br /> see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube <br /> cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing <br /> substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximally tolerated dose (MTD) of intraperitoneal administration of an
Edmonston's strain measles virus genetically engineered to produce sodium iodine symporter
(NIS) (measles virus [MV]-NIS) in patients with recurrent ovarian cancer, delivered by
adipose tissue derived mesenchymal stem cells (MSC). (Phase I) II. To assess the 12 month
overall survival of patients treated with this regimen. (Phase II)
SECONDARY OBJECTIVES:
I. To assess the tolerability of this regimen. (Phase II) II. To assess the 4 month
progression free survival of patients treated with this regimen. (Phase II) III. To assess
the response rate, progression-free survival, and overall survival of patients treated with
this regimen. (Phase II)
TRANSLATIONAL OBJECTIVES:
I. To assess the time course of viral gene expression and virus elimination and
biodistribution of virally infected cells at various time points after infection with MV-NIS
versus MSC delivered MV-NIS using single-photon emission computed tomography (SPECT)/computed
tomography (CT) imaging. (Phase II) II. To assess viremia, viral replication, and measles
virus shedding/persistence following intraperitoneal administration. (Phase II) III. To
assess humoral and cellular immune response to the injected virus. (Phase II) IV. To assess
in a preliminary fashion the development of antitumor immune response. (Phase II)
OUTLINE: This is a phase I, dose-escalation study followed by phase II study.
Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter
intraperitoneally (IP) over 30 minutes on day 1 of cycle 1 and MV-NIS infected mesenchymal
stem cells (MSC) (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of
subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of
disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for up to 5
years.
Treatments and/or Procedures
Oncolytic measles virus encoding thyroidal sodium iodide symporter
Given IP
Mesenchymal stem cell transplantation
Given IP
Laboratory biomarker analysis
Correlative studies
Outcome Measures
Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.
Primary
Proportion of patients alive at 12 months (Phase II)
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated.
Primary
Toxicity profiles by dose level and patient (Phase I)
Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.
Primary
Overall toxicity incidence (Phase I)
Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.
Primary
Number and severity of adverse events (Phase I)
All adverse events (overall, and by dose-level) will be tabulated and summarized. The grade 3+ adverse events will also be described and summarized in a similar fashion.
Primary
Maximum tolerated dose (MTD) (Phase I)
Will be defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients).
Secondary
Rate of progression free survival (Phase II)
Kaplan-Meier survival curves and logrank tests will be used to estimate the progression-free time distributions of the study patients and study patient subsets defined by disease and/or correlative characteristics.
Secondary
Progression free survival (Phase II)
The distribution of progression-free survival will be estimated using Kaplan-Meier survival curves and logrank tests. In addition, comparisons of overall progression free survival in patients treated with MV-NIS/MSC will be made to patients enrolled on the prior MV-CEA and MV-NIS trial in an exploratory manner.
Secondary
Overall survival (Phase II)
The distribution of survival time will be estimated using Kaplan-Meier survival curves and logrank tests. In addition, comparisons of overall survival in patients treated with oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS)/mesenchymal stem cells (MSC) will be made to patients enrolled on the prior MV-carcinoembryonic antigen (CEA) and MV-NIS trial in an exploratory manner.
Secondary
Tumor response (Phase II)
Will be defined as complete response or partial response.
Other
Cellular immune response to the injected virus (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Other
Humoral immune response to the injected virus (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Other
Measles virus shedding/persistence following intraperitoneal administration (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Other
Incidence of viremia (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Other
Incidence of viral replication (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Other
Antitumor immune response (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Other
Virus elimination and biodistribution of virally infected cells by single photon emission computed tomography imaging (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Other
Time course of viral gene expression (Phase II)
Descriptive statistics and simple scatterplots will form the basis of presentation of these data. Correlations between these laboratory values and other outcome measures will be carried out using Spearman's coefficients, chi squared tests, Wilcoxon rank-sum tests, Kaplan-Meier curves, and Cox proportional hazards models, where appropriate.
Study Criteria
Inclusion Criteria:
- Must have:
- Recurrent or progressive ovarian cancer, primary peritoneal cancer or fallopian
tube cancer after prior treatment with platinum and taxanes
- Histologic confirmation of the original primary tumor
- Prior bilateral oophorectomy
- The following histologic epithelial cell types are eligible: serous adenocarcinoma,
endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma,
clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma,
malignant Brenner's tumor, or adenocarcinoma not otherwise specified (NOS)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2
- Absolute neutrophil count (ANC) >= 1500/uL (obtained =< 7 days prior to registration)
- Platelet (PLT) >= 100,000/uL (obtained =< 7 days prior to registration)
- Total bilirubin =< upper normal limit (obtained =< 7 days prior to registration)
- Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN) (obtained =< 7
days prior to registration)
- Creatinine =< 1.5 x ULN (obtained =< 7 days prior to registration)
- Hemoglobin (Hgb) >= 9.0 g/dL (obtained =< 7 days prior to registration)
- Normal cardiac function as defined by a normal ejection fraction by multi gated
acquisition scan (MUGA) or echocardiogram
- Provide informed written consent
- Willing to return to Mayo Clinic Rochester for follow-up
- Life expectancy >= 12 weeks
- Willing to provide all biologic specimens as required by the protocol
- Measurable disease by exam or CT scan, or for patients with cancer antigen (CA)-125
elevation or with microscopic residual but without measurable disease on imaging,
willingness to undergo laparoscopy for evaluation of treatment effect if no
radiographic progression after 6 treatment cycles
- CD4 count >= 200/uL or >= 15% of peripheral blood lymphocytes
Exclusion Criteria:
- Epithelial tumors of low malignant potential, stromal tumors, and germ cell tumors of
the ovary
- Known standard therapy for the patient's disease that is potentially curative or
definitely capable of extending life expectancy; subjects will be excluded if this is
their first relapse and they have recurred > 6 months from completion of primary
(adjuvant) chemotherapy
- Active infection =< 5 days prior to registration
- History of tuberculosis or history of tuberculosis skin test purified protein
derivative (PPD) positivity
- History of other malignancy =< 5 years prior to registration except for non-melanoma
skin cancer, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS)
- Any of the following prior therapies:
- Chemotherapy =< 3 weeks prior to registration
- Immunotherapy =< 4 weeks prior to registration
- Biologic therapy =< 4 weeks prior to registration
- Extensive abdominal surgery if it includes enterotomy(ies) =< 3 weeks prior to
registration; this criterion does not apply to placement of the peritoneal
Port-A-Cath or lysis of adhesions at the time of registration
- Any viral or gene therapy prior to registration
- Radiation therapy to the abdomen or pelvis
- New York Heart Association classification III or IV, known symptomatic coronary artery
disease, or symptoms of coronary artery disease on systems review, or known cardiac
arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])
- Other cardiac or pulmonary disease that, at the investigators discretion, can impair
treatment safety
- Requiring blood product support
- Central nervous system (CNS) metastases or seizure disorder
- Human immunodeficiency virus (HIV)-positive test result or history of other
immunodeficiency
- History of organ transplantation
- History of chronic hepatitis B or C
- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
considered investigational (utilized for a non-Food and Drug Administration
[FDA]-approved indication and in the context of a research investigation)
- Intra-abdominal disease > 8 cm in diameter at the time of registration, intrahepatic
disease, or disease beyond the abdominal cavity; patients with intra-abdominal lymph
node involvement are eligible based on biodistribution data indicating viral
dissemination to lymph nodes following intraperitoneal administration
- Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled
steroids
- Exposure to household contacts =< 15 months old or household contact with known
immunodeficiency
- Allergy to measles vaccine or history of severe reaction to prior measles vaccination
- Allergy to iodine; this does not include reactions to intravenous contrast materials
- Any other pathology or condition where the principle investigator may deem to
negatively impact treatment safety